United Therapeutics | UTHR

Stock Price
400.52
Daily Change
20.05 5.27%
Monthly
32.44%
Yearly
15.88%
Q3 Forecast
397.20

Peers Price Chg Day Year Date
Amarin 15.33 0.30 2.00% 27.64% Sep/05
Ardelyx 6.52 -0.05 -0.76% 16.43% Sep/05
Baxter International 24.42 0.84 3.56% -37.34% Sep/05
Bayer 28.16 -0.42 -1.47% -1.83% Sep/06
Biogen 140.67 0.73 0.52% -30.02% Sep/05
BioMarin Pharmaceutical 57.77 1.02 1.80% -31.29% Sep/05
Gilead Sciences 115.05 2.28 2.02% 46.10% Sep/05
GlaxoSmithKline 1,476.00 7.00 0.48% -10.63% Sep/05
Halozyme Therapeutics 74.93 1.53 2.08% 26.55% Sep/05
Insmed 145.10 2.57 1.80% 104.25% Sep/05
Ionis Pharmaceuticals 61.23 1.88 3.17% 30.58% Sep/05
J&J 178.43 -0.33 -0.18% 8.51% Sep/05
Moderna 25.14 0.86 3.54% -65.54% Sep/05
Pfizer 24.88 0.34 1.39% -12.95% Sep/05
PTC Therapeutics 57.26 -0.75 -1.29% 81.55% Sep/05
Regeneron Pharmaceuticals 573.38 6.16 1.09% -49.30% Sep/05
Sarepta Therapeutics 18.71 0.25 1.35% -85.49% Sep/05
Teva Pharmaceutical Industries 6,362.00 87.00 1.39% -5.45% Sep/07
United Therapeutics 400.52 20.05 5.27% 15.88% Sep/05
Vertex Pharmaceuticals 396.12 -0.81 -0.20% -15.39% Sep/05

Indexes Price Day Year Date
USND 21700 -7.31 -0.03% 30.01% Sep/05
US400 3297 16.31 0.50% 12.16% Sep/05

United Therapeutics traded at $400.52 this Friday September 5th, increasing $20.05 or 5.27 percent since the previous trading session. Looking back, over the last four weeks, United Therapeutics gained 32.44 percent. Over the last 12 months, its price rose by 15.88 percent. Looking ahead, we forecast United Therapeutics to be priced at 397.20 by the end of this quarter and at 387.39 in one year, according to Trading Economics global macro models projections and analysts expectations.

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening conditions. The Company market and sell four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution, which includes the Tyvaso Inhalation System; Orenitram (treprostinil) Extended-Release Tablets; and Adcirca (tadalafil) Tablets. In the United States, the Company also markets and sells an oncology product, Unituxin (dinutuximab) Injection, which is approved for the treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin. The Company is also engaged in early-stage research and development of a number of organ transplantation-related technologies, including regenerative medicine, xenotransplantation, and ex-vivo lung perfusion.